JEFF BEZOS JUST EMERGED FROM STEALTH WITH A $41 BILLION AI STARTUP CALLED PROMETHEUS
$12 billion raised. Valued at $41 billion. Coming out of stealth today.
The backers: Bezos personally, JPMorgan, BlackRock, Goldman Sachs, DST Global, and Arch Venture Partners.
The mission: do for engineering and manufacturing what large language models did for text.
Bezos is calling it an "artificial general engineer." Instead of training on words from the internet, Prometheus ingests data from the physical world to accelerate the manufacturing of skyscrapers, smartphones, jet engines, and everything in between.
In Bezos' own words: "Something that today was going to take 100 engineers 10 years to build, if you can change that to taking 10 engineers one year to build, you're just going to get way more things built."
This is Bezos' first CEO role since stepping down from Amazon in 2021. He's co-leading it with Vik Bajaj, former Google X executive.
(Source Semafor)
SCOOP: The State Department has uncovered several "birth tourism networks" in West Africa, Europe, and North Africa, where embassies found evidence of plans to facilitate individuals traveling to the U.S. to give birth.
https://t.co/x9ZNwr1PgL
17-year-old Cordarius Hobbs allegedly broke into Billy Blair and his wife Virginia Carol Blair's home last Wednesday and killed the couple. Billy was 74, Virginia was 71. He has been arrested for their murders. Are we tired of being prey yet? Another "isolated incident" that just keeps happening over and over.
Major milestone for Oklo’s Aurora powerhouse @INL: @ENERGY just approved our Preliminary Documented Safety Analysis (PDSA), making Aurora-INL the largest electric-output reactor design publicly announced to receive PDSA approval under DOE's Reactor Pilot Program to date.
The approval advances Aurora-INL’s preliminary safety basis and creates a framework that future Aurora deployments can build on to make each successive project easier to replicate.
For Oklo, Aurora-INL is more than our first powerhouse. It's the foundation for repeatable deployment.
More ->
https://t.co/nHdUBeT22E
The weirdest thing about longevity tech is that it probably won’t feel like sci fi when it arrives.
It’ll just be some clean clinic ad with soft music, a calm doctor, and a guy getting ten good years of his life back.
Sounds insane today.
In 20 years it might be as normal as laser eye surgery.
If this was proven safe, would you do it?
If you stab someone and kill them that is murder and you should face justice just like Karmelo Anthony in Collin County, Texas.
But if you’re name is Iryna Zarutska and you are stabbed in the neck and murdered on a train in North Carolina then you’re killer gets to have his trial postponed again because he acted out in court today and said he was having a “body emergency.”
You know who had a body emergency?
Iryna and Austin.
They were both stabbed and murdered.
Last week, they tried to hide video of the police cuffing a White man a Sikh had stabbed to death.
This week, they’re trying to hide the video of an African migrant cutting a White man’s head off.
Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀
Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman
The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases
The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression
“This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.”
Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential.
“This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.”
Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment
Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies.
Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform.
About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults
While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments
About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at https://t.co/GDRzIctoot (NCT07290244): https://t.co/Jj9cnu2M6w
For more information, visit https://t.co/msih0JTYfF or follow on social media
https://t.co/pEGPJjFjnQ
Introducing Claude Fable 5: a Mythos-class model that we’ve made safe for general use.
Its capabilities exceed those of any model we’ve ever made generally available.
The truth is that there are VASTLY more hate crimes, especially aggravated rape and murder, per person by Blacks against Whites than the other way around.
The is not remotely debatable, as the numbers are so extremely lopsided!